Imperial College London
Portrait Picture

ProfessorAbbasDehghan

Faculty of Medicine, School of Public Health

Professor in Molecular Epidemiology
 
 
 
//

Contact

 

+44 (0)20 7594 3347a.dehghan CV

 
 
//

Location

 

Sir Michael Uren HubWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Nazarzadeh:2021:10.1016/S0140-6736(21)01920-6,
author = {Nazarzadeh, M and Bidel, Z and Canoy, D and Copland, E and Wamil, M and Majert, J and Smith, Byrne K and Sundström, J and Teo, K and Davis, BR and Chalmers, J and Pepine, CJ and Dehghan, A and Bennett, DA and Smith, GD and Rahimi, K and Blood, Pressure Lowering Treatment Trialists Collaboration},
doi = {10.1016/S0140-6736(21)01920-6},
journal = {Lancet},
pages = {1803--1810},
title = {Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis.},
url = {http://dx.doi.org/10.1016/S0140-6736(21)01920-6},
volume = {398},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUND: Blood pressure lowering is an established strategy for preventing microvascular and macrovascular complications of diabetes, but its role in the prevention of diabetes itself is unclear. We aimed to examine this question using individual participant data from major randomised controlled trials. METHODS: We performed a one-stage individual participant data meta-analysis, in which data were pooled to investigate the effect of blood pressure lowering per se on the risk of new-onset type 2 diabetes. An individual participant data network meta-analysis was used to investigate the differential effects of five major classes of antihypertensive drugs on the risk of new-onset type 2 diabetes. Overall, data from 22 studies conducted between 1973 and 2008, were obtained by the Blood Pressure Lowering Treatment Trialists' Collaboration (Oxford University, Oxford, UK). We included all primary and secondary prevention trials that used a specific class or classes of antihypertensive drugs versus placebo or other classes of blood pressure lowering medications that had at least 1000 persons-years of follow-up in each randomly allocated arm. Participants with a known diagnosis of diabetes at baseline and trials conducted in patients with prevalent diabetes were excluded. For the one-stage individual participant data meta-analysis we used stratified Cox proportional hazards model and for the individual participant data network meta-analysis we used logistic regression models to calculate the relative risk (RR) for drug class comparisons. FINDINGS: 145939 participants (88500 [60·6%] men and 57429 [39·4%] women) from 19 randomised controlled trials were included in the one-stage individual participant data meta-analysis. 22 trials were included in the individual participant data network meta-analysis. After a median follow-up of 4·5 years (IQR 2·0), 9883 participants were diagnosed with new-onset type 2 diabetes. Systolic blood pressure reducti
AU  - Nazarzadeh,M
AU  - Bidel,Z
AU  - Canoy,D
AU  - Copland,E
AU  - Wamil,M
AU  - Majert,J
AU  - Smith,Byrne K
AU  - Sundström,J
AU  - Teo,K
AU  - Davis,BR
AU  - Chalmers,J
AU  - Pepine,CJ
AU  - Dehghan,A
AU  - Bennett,DA
AU  - Smith,GD
AU  - Rahimi,K
AU  - Blood,Pressure Lowering Treatment Trialists Collaboration
DO  - 10.1016/S0140-6736(21)01920-6
EP  - 1810
PY  - 2021///
SP  - 1803
TI  - Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis.
T2  - Lancet
UR  - http://dx.doi.org/10.1016/S0140-6736(21)01920-6
UR  - https://www.ncbi.nlm.nih.gov/pubmed/34774144
VL  - 398
ER  -
Download